Stanley Hsia to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Stanley Hsia has written about Dose-Response Relationship, Drug.
Connection Strength
0.113
-
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 06; 406(10520):2631-2643.
Score: 0.057
-
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18; 393(11):1065-1076.
Score: 0.056